Format

Send to

Choose Destination
J Comp Eff Res. 2020 Feb;9(3):191-199. doi: 10.2217/cer-2019-0163. Epub 2020 Jan 9.

Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison.

Author information

1
Evidera, Real-World Evidence, Waltham, MA 02451, USA.
2
Evidera, Real-World Evidence, London, UK.
3
Payer Models & Real-World Data, AstraZeneca, Mölndal, Sweden.
4
Sarah Cannon Research Institute, London, UK.
5
AstraZeneca, Oncology Business Unit, Global Medical Affairs, Gaithersburg, MD 20878, USA.

Abstract

Aim: To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. Patients & methods: In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan-Meier methods and Cox regression models were utilized. Results: Median overall survival was 11.2 months (95% CI: 7.2-16.9) for durvalumab versus 8.2 months (95% CI: 6.7-9.8) for chemotherapy (hazard ratio: 0.63; 95% CI: 0.48-0.84). Conclusion: As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.

KEYWORDS:

chemotherapy; durvalumab; indirect treatment comparison; observational; overall survival; urothelial carcinoma

PMID:
31916448
DOI:
10.2217/cer-2019-0163
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center